ELTROMBOPAG OLAMINE (eltrombopag olamine) by Novartis is tpo-receptor agonist that interacts with the transmembrane domain of the human tpo-receptor (also known as cmpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production. Approved for thrombocytopenia in adult, older with persistent, chronic immune thrombocytopenia (itp) and 9 more indications. First approved in 2024.
Drug data last refreshed 18h ago
TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Worked on ELTROMBOPAG OLAMINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State
Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia